Alps Advisors Inc. Purchases 53,856 Shares of Amylyx Pharmaceuticals, Inc. $AMLX

Key Points

• Alps Advisors increased its Amylyx stake by 47.9% in the third quarter, adding 53,856 shares to hold 166,303 shares valued at about $4.84 million. Institutional investors collectively owned 95.84% of the stock.
• Analyst sentiment was broadly positive: the stock had a consensus “Buy” rating and an average price target of $44.14, though one firm rated it “Sell.” HC Wainwright also initiated coverage with a “Strong Buy” rating.
• Amylyx reported a quarterly loss of $0.38 per share, matching expectations. Two insiders sold shares to cover tax withholding on vested equity awards; insiders sold 60,374 shares in total over the prior 90 days.

Alps Advisors Inc. boosted its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 47.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 166,303 shares of the company's stock after acquiring an additional 53,856 shares during the quarter. Alps Advisors Inc. owned 0.15% of Amylyx Pharmaceuticals worth $4,839,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Commonwealth Equity Services LLC bought a new position in shares of Amylyx Pharmaceuticals during the third quarter valued at $590,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Amylyx Pharmaceuticals in the 3rd quarter worth about $187,000. Profund Advisors LLC boosted its holdings in Amylyx Pharmaceuticals by 138.7% in the third quarter. Profund Advisors LLC now owns 49,435 shares of the company's stock worth $1,439,000 after purchasing an additional 28,725 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of Amylyx Pharmaceuticals by 10.7% during the 3rd quarter. ProShare Advisors LLC now owns 17,360 shares of the company's stock valued at $505,000 after buying an additional 1,675 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Amylyx Pharmaceuticals by 29.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,901 shares of the company's stock valued at $671,000 after buying an additional 5,206 shares during the period. 95.84% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO James M. Frates sold 10,810 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the sale, the chief financial officer owned 233,625 shares in the company, valued at approximately $7,560,105. This represents a 4.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Gina Mazzariello sold 9,536 shares of the firm's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.46, for a total value of $309,538.56. Following the completion of the sale, the insider owned 190,838 shares of the company's stock, valued at approximately $6,194,601.48. This represents a 4.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 60,374 shares of company stock worth $1,815,257 in the last 90 days. Company insiders own 10.90% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on AMLX. Weiss Ratings reissued a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a report on Tuesday, November 3rd. Stifel Nicolaus set a $45.00 price target on shares of Amylyx Pharmaceuticals in a research report on Thursday. Mizuho lifted their price target on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 18th. Robert W. Baird increased their target price on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an "outperform" rating in a report on Wednesday, August 19th. Finally, HC Wainwright initiated coverage on Amylyx Pharmaceuticals in a research note on Thursday. They issued a "strong-buy" rating for the company. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $44.14.

Amylyx Pharmaceuticals Stock Performance

Shares of NASDAQ AMLX opened at $29.50 on Monday. Amylyx Pharmaceuticals, Inc. has a 12-month low of $10.83 and a 12-month high of $41.14. The firm's 50-day moving average price is $30.00 and its 200-day moving average price is $20.41. The stock has a market capitalization of $3.29 billion, a price-to-earnings ratio of -20.49 and a beta of -0.09.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.38) EPS for the quarter, hitting the consensus estimate of ($0.38). On average, equities analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.49 EPS for the current fiscal year.

Key Stories Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $55 price target, while forecasting quarterly losses to narrow from $0.38 per share in Q1 2027 to $0.32 in Q4 2027. The rating and target may support investor optimism. Analyst estimates and rating
• Neutral Sentiment: Amylyx reported a Q3 2026 loss of $0.38 per share, matching the consensus estimate. The in-line result was not a positive earnings surprise. Third-quarter financial results
• Neutral Sentiment: The company’s Q3 2026 earnings-call transcript was published, but the provided coverage does not detail additional announcements or outlook changes from the call. Q3 2026 earnings-call transcript

About Amylyx Pharmaceuticals

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.